Heidelberg, Germany – May 30, 2024 – Full-Life Technologies (Full-Life), a fully integrated global radiotherapeutics company, today announced it has received clearance of its Investigational New Drug (IND) Application from the U.S. Food and Drug Administration (FDA) for clinical trials of ²²⁵Ac-FL-020, its PSMA-targeted radiopharmaceutical for the treatment of metastatic castration-resistant prostate cancer (mCRPC).

Gembloux, Belgium – May 17, 2024 – Full-Life Technologies (Full-Life), a fully integrated global radiotherapeutics company, today announced the appointment of Mark S. de Jong, PhD, to the newly created position of Chief Technical Officer (CTO).

Shanghai, China, and Heidelberg, Germany – May 10, 2024 – Full-Life Technologies (Full-Life), a fully integrated global radiotherapeutics company, today announced that it will present preclinical data of FL-091 (a NTSR1-targeted RDC program) in an oral presentation at the 2024 SNMMI.

Full-Life Technologies announced that the company has presented the preclinical data of ²²⁵Ac-FL-020 (a PSMA-targeted RDC program) at the 2024 Annual Meeting of the American Association for Cancer Research (AACR) in San Diego, California.

Gembloux, Belgium – Mar. 26, 2024 – Full-Life Technologies (“Full-Life”), today announced the recent achievement of its subsidiary “Full-Life Technology Europe” has obtained a Nuclear Permit for a class IIA facility from the Belgium Federal Agency for Nuclear Control (“FANC”).